A new compound, Copper (II) has been synthesized and described in association with the schiff base ligand of thiazole derivatives. The structural composition of the novel substance was elucidated through the application of physicochemical approaches. The complex's analytical results validate the creation of 1:1 (M:L) complex and are consistent with the molecular formula proposed. The ligand and Cu(II) complex were investigated against two Gram-positive bacteria Bacillus subtilis and Staphylococcus aureus, two Gram-negative bacteria Escherichia coli and Proteus vulgaris. The antibacterial efficacy is arranged as follows: gentamicin, ampicillin > [CuL(H₂O)Cl₂]2H₂O > L. Using cisplatin as a reference, the cytotoxicity of the Cu(II) complex and ligand against the human liver (Hep-G2) and breast MCF7 cancer cell lines was assessed. The complex of [CuL(H₂O)Cl₂]2H₂O showed the maximum activity against the two cell lines.